Haisen Pharm(001367.SZ)

Company Encyclopedia
View More
name
Haisen Pharm
001367.SZ
Zhejiang Haisen Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical active pharmaceutical ingredient and intermediates in China. The company offers APIs for anti-gastric ulcer, antilipemic agent, antipyretic analgesics, antidepressant, analgesic, antibacterial agent, antipyretic analgesics, histamines drug, and anticonvulsant. It also provides chemical product for intermediates and food additives.
3.027 T
001367.SZMarket value -Rank by Market Cap -/-

Financial Score

02/01/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking69/222
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE9.05%B
    • Profit Margin24.26%A
    • Gross Margin48.56%B
  • Growth ScoreB
    • Revenue YoY17.50%B
    • Net Profit YoY3.45%C
    • Total Assets YoY12.08%B
    • Net Assets YoY9.92%B
  • Cash ScoreB
    • Cash Flow Margin412.17%C
    • OCF YoY17.50%B
  • Operating ScoreD
    • Turnover0.34D
  • Debt ScoreA
    • Gearing Ratio8.69%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Hong Kong Stock Movement: BAO PHARMA-B's full circulation plan triggers a sharp decline in stock price, as the market reassesses liquidity and valuation risks

    BAO PHARMA-B fell 10.06%; Innovent Biologics rose 2.62%, with a transaction volume of HKD 120 million; BeiGene rose 2.45%, with a transaction volume of HKD 63.77 million; CanSino Biologics fell 1.06%, with a transaction volume of HKD 50.03 million; Kelun-Biotech rose 0.71%, with a market capitalization of HKD 92.1 billion

    HK Stock Movers Tracker·
    HK
    02659
    -10.12%
    HK Stock Movers Tracker·
    HK
    02659
    -10.12%

    Weight-Loss Drug Prices Drop in China as Patent Expiry Nears

    Prices of weight-loss drugs in China, including Wegovy and Mounjaro, are dropping as patent expirations approach. Wegovy's price has halved to CNY987.48 from CNY1,893.67, while Mounjaro's presale price is now as low as CNY450, down from CNY2,180. Novo Nordisk's price cuts aim to enhance patient compliance. The patent for semaglutide (Wegovy) expires on March 20, prompting domestic firms to prepare generic versions. This price reduction is expected to impact the industry and future weight-loss drug pricing significantly.

    Yicai·
    Yicai·

    Haisen Pharm released its performance for the first three quarters, with a net profit attributable to the parent company of 88.2096 million yuan, an increase of 1.45%

    Haisen Pharm released its Q3 2025 report, with operating revenue for the first three quarters at 359 million yuan, a year-on-year increase of 12.13%. The net profit attributable to the parent company was 88.2096 million yuan, a year-on-year increase of 1.45%. The net profit after deducting non-recurring gains and losses was 84.758 million yuan, a year-on-year decrease of 1.56%. The basic earnings per share were 0.59 yuan

    Zhitong·
    SZ
    001367
    0.00%
    Zhitong·
    SZ
    001367
    0.00%

    Haisen Pharm: Net profit of 60.7942 million yuan in the first half of 2025, a year-on-year increase of 4.74%

    Haisen Pharm announced that in the first half of 2025, operating income was 242 million yuan, a year-on-year increase of 14.93%; net profit was 60.7942 million yuan, a year-on-year increase of 4.74%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert reserves into share capital

    Zhitong·
    SZ
    001367
    0.00%
    Zhitong·
    SZ
    001367
    0.00%

    The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin falling over 6%

    The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin dropping over 6%, and HYBIO, Cosunter, Haisen Pharm, TY PHAR., and others following suit

    Zhitong·
    SZ
    002275
    -0.21%
    SZ
    300199
    -1.92%
    SZ
    300436
    -2.10%
    Zhitong·
    SZ
    002275
    -0.21%
    SZ
    300199
    -1.92%
    SZ
    300436
    -2.10%
    © 2026 Longbridge｜Disclaimer